

19 September 2024

Notification under Listing Rule 4.3D

Perth, Australia, and Minneapolis, USA: TrivarX Limited ("the Company") (ASX: TRI) advises that, following the finalisation of the audit of the Group's financial accounts for the year ended 30 June 2024, a change to the results and the composition of the net asset position reported in the Appendix 4E – Preliminary Final Report ("Appendix 4E") lodged with the Australian Securities Exchange ("ASX") on 29 August 2024 was identified and incorporated into the audited Annual Report for the financial year ended 30 June 2024 lodged today.

The impact on the numbers presented is shown below:

	Appendix 4E	Audited Financial Statements	Change	Note
Loss before income tax expense	(1,237,093)	(1,434,616)	(197,523)	(i)
Trade and other payables	948,691	938,044	10,647	(ii)

- (i) the recognition of the fair value of share options issued to key management personnel and officers of the Company in accordance with AASB 2 – Share Based Payments after a technical analysis by the auditor. As a result, the loss before income tax expense in the Appendix 4E was understated by \$197,523.
- (ii) the reduction of trade and other payables following initial misclassification of GST on an Australian invoice. As a result, trade and other payables in the Appendix 4E was overstated by \$10,647.

It is noted that these adjustments do not impact cash.

The Board does not consider that the noted changes materially affect current or future financial performance or financial position of the Company. The Board notes this change under ASX Listing Rule 4.3D for completeness.

This announcement is authorised for release by the Board of Directors of TrivarX Limited

ENDS

Investor Enquiries:

Henry Jordan – Six Degrees Investor Relations

Henry.jordan@sdir.com.au

+61 431 271 538

About TrivarX Limited:

TrivarX (ASX: TRI) (OTCPINK: MDBIF) is a mental health technology company pioneering the use of objective measures to aid in the early detection and screening of mental health conditions. The Company was founded in Australia, with offices located in Perth (WA) and Minneapolis (MN, USA). TrivarX is listed on the Australian Securities Exchange Ltd and trades on the OTCQB Venture Market. Investors can find additional information on www.otcm Markets.com and www.asx.com.au